Type:7 Tablets
Generic Name:Atorvastatin + Ezetimibe
Manufacturer:Beacon Pharmaceuticals Ltd.
Price:৳112.00
Hypercholesterolaemia, Primary Hyperlipidemia
May be taken with or without food.
Oral Hypercholesterolaemia Adult: Per tablet contains atorvastatin 10 mg and ezetimibe 10 mg: Usual starting: 1 tablet once daily.
Safety and efficacy not established
Hypersensitivity; active liver disease or unexplained persistent elevated liver function tests. Pregnancy and lactation.
Atorvastatin competitively inhibits HMG-CoA reductase, the enzyme that catalyses the conversion of HMG-CoA to mevalonate which is an early rate-limiting step in cholesterol biosynthesis. Ezetimibe inhibits the absorption of cholesterol from the intestine, thus decreasing the delivery of intestinal cholesterol to the liver.
Hepatic impairment; patients consuming substantial quantities of alcohol with a history of liver disease. Not recommended for use in children <10 yr. Lactation: Because of the potential for adverse reactions in nursing infants, women taking this drug should not breast feed. Contraindicated in breastfeeding women.
1-10% Increased ALT (5%),Increased AST (4%),Musculoskeletal pain (4%),Abdominal pain (3%),Nausea (3%),Arthralgias (3%),Muscle weakness (2%),Dizziness (2%),Hyperkalemia (2%),Hot flushes (2%),Coughing (2%),Bronchitis (2%),Sinusitis (2%)
Pregnancy Category: X Lactation: Because of the potential for adverse reactions in nursing infants, women taking this drug should not breast feed. Contraindicated in breastfeeding women.
Atorvastatin: Increases digoxin levels; increases anticoagulant effect of warfarin. Avoid the combination of HMG-CoA reductase inhibitors and fibrates. Ezetimibe: Cholestyramine decreases AUC of ezetimibe by approx 55%; ciclosporin may increase ezetimibe levels. Potentially Fatal: Antacids decrease atorvastatin levels; colestipol decreases atorvastatin plasma levels; propranolol decreases antihyperlipidaemic activity of atorvastatin.